Corvus Pharmaceuticals, Inc. 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sure. Maybe we'll start with who's Corvus.

Yeah. We're a clinical stage company.

We're focused on developing novel immune modulators for the treatment of cancer and immune diseases. Our lead program, soquelitinib, is a novel oral ITK inhibitor.

It's in a registrational phase III trial for peripheral T-cell lymphoma. In addition, we're in a phase II trial called the CR-01 trial for moderate to severe atopic dermatitis. Our partner, Angel Pharmaceuticals, is also studying soquelitinib in an AD trial as well. Soquelitinib represents a pipeline and a product opportunity for us. We have a number of studies planned, including asthma and HS, that will start this year. We have strong composition of matter patents that go through November of 2037, and with pharmaceutical extensions, 2042. The ITK is a platform technology for us, so we have a number of next generations and backups in development.

Sure. How are we different? I would say three things. We're an oral tablet, the mechanism of action, as you mentioned, and also the selectivity and safety of the drug. We're an oral tablet, which is important to note because obviously in atopic dermatitis, the primary therapies are injectables, so there's an unmet need for a novel and safe product. In terms of the mechanism of action, ITK stands for interleukin-2-inducible T-cell kinase. It's involved in T-cell receptor signaling and differentiation.

Essentially how we work is that we block Th2 and Th17 and those respective cytokines. Think IL-4, 5, 13, like DUPIXENT, think IL-17 like Taltz. In addition, what we've shown is that we can shift or switch Th17 cells to become Treg cells. So we feel like we are actually rebalancing the immune system, not suppressing it. In addition, in terms of differentiation, ITK has very limited tissue distribution. It's found only on T-cells and NK cells.

We are highly selective just for ITK, so we expect limited off-target effects, and we've seen that to date in our clinical data. We've had a very good safety profile.

Sure. Well, maybe to start with the clinical outcomes because we've had very strong data to date. Our safety profile is similar to placebo in atopic dermatitis. Our efficacy profile is similar to a JAK or a biologic. It depends whether you're looking at EASI 75 or IGA 0/1.

Relating to the biomarker data, it does support the clinical profile. We showed at the SID data, we had data showing a dose response effect in reducing Th2 cells- and those respective cytokines, so we reduced IL-4, 5, 13, and TARC.

In terms of Th17, we actually showed a reduction in RORγt, which is a transcription factor for IL-17. And we showed an increase in Tregs both on therapy and off therapy, and we saw an increase as well in Bach2, which supports Treg survival. So we think now this biomarker data is supporting our clinical data.